Drugs / POTASSIUM CITRATE ANHYDROUS
POTASSIUM CITRATE ANHYDROUS
also known as
Potassium Citrate · UroCit-K · Cymaclear · E-332(ii) · Effercitrate · Ins no.332(ii) · Ins-332(ii) · K-cit-v · +9 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Sibnayal | — | 2021-04-30 | europa.eu ↗ |
| Approved | US (FDA) | UROCIT-K | — | 1985-08-30 | fda.gov ↗ |
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06819111 | Jul 2026 → Jul 2027 expected | nephrolithiasis | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06335537 | May 2025 → Jul 2026 overdue | urolithiasis | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07408076 | Feb → Aug 2026 overdue | nephrolithiasis | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00913796 | Dec 2007 → Mar 2010 | bone disorder, metabolic acidosis, mineral metabolism disease | University of Zurich | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06819553 | Nov 2024 → Feb 2025 overdue | ureterolithiasis, urolithiasis | Zagazig University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05918029 | Aug 2024 → Aug 2026 overdue | bone resorption disease, chronic kidney disease | Albert Einstein College of Medicine | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01756547 | Jan → Dec 2013 | nephrocalcinosis | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 3 | NCT00004284 | Apr 1995 → ? | idiopathic hypercalciuria, nephrolithiasis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06966635 | Apr 2024 → Dec 2025 overdue | gout, nephrolithiasis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03007160 | Jul 2016 → Sep 2020 | urolithiasis | Dawnrays Pharmaceutical (Holdings) Limited | Unknown | No outcome recorded |
| Phase 4 | NCT02373384 | Feb 2015 → Feb 2017 | nephrolithiasis | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT02653560 | Sep 2012 → Jan 2015 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00357331 | Aug 2006 → Apr 2011 | postmenopausal osteoporosis | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00120731 | Jul 2005 → May 2007 | nephrolithiasis | Children's Mercy Hospital Kansas City | Withdrawn | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT04651088 Comparator | Jul → Dec 2026 expected | urolithiasis | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03809884 Comparator | Dec 2019 → Jul 2024 | hypertensive disorder | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00509405 Comparator | Jul 2007 → May 2010 | — | Kantonsspital Baselland Bruderholz | Completed | No outcome recorded |
| Phase 4 | NCT06003348 Comparator | Dec 2023 → May 2028 expected | urolithiasis | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05365477 Comparator | Aug 2022 → Sep 2025 | nephrolithiasis | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT07202832 Comparator | Oct 2025 → Aug 2026 overdue | urinary tract infection | Assiut University | Not yet recruiting | No outcome recorded |
| — | NCT05389995 Comparator | Aug 2022 → Apr 2025 overdue | urolithiasis | Northwestern University | Active not recruiting | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POTASSIUM CITRATE ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Cymaclear | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | E-332(ii) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Effercitrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Ins no.332(ii) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Ins-332(ii) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | K-cit-v | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | K-citrate | “The study medication, K-citrate, or placebo, was dispensed through the New York Presbyterian Hospital (NYPH) pharmacy.” NCT00357331 ↗ |
| Known as | Kalii citras | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Kcit | “Prescription potassium citrate (Kcit) can be cost-prohibitive for many patients, leading to non-compliance.” NCT07408076 ↗ |
| Known as | NSC-760107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Pot cit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Pot cit eff | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Potassium Citrate | “Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.” NCT05365477 ↗ |
| Known as | Potassium citrate component of adv-7103 monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | Potassium citrate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Known as | UroCit-K | “Patients will receive slow-release potassium citrate (UroCit-K), potassium magnesium citrate (powder), or potassium magnesium citrate (tablets).” NCT06819111 ↗1“Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.” NCT04651088 ↗ |
| Known as | Urocit-k 5meq | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200458 ↗ |
| Action | Inhibit | “Potassium citrate is readily absorbed from the gastrointestinal tract, and after being excreted in the urine, it inhibits the crystallization of stone forming calcium salts by...” NCT00120731 ↗ |
| Modality | Small molecule | — CHEMBL1200458 ↗ |
| Route | Oral | “Patients receive potassium phosphate or potassium citrate tablets twice a day for 3 years.” NCT00004284 ↗ |